Scholarlink

Antithrombotic and antiplatelet agents have been in use for over 100 years, with many listed as WHO essential medicines. Mortality and morbidity caused by cardiovascular diseases and due to arterial and venous thrombosis are increasing globally. The old legacy products such as heparin and warfarin, and the newer generation of agents, such as DOACs and anti-platelet agents, are needed to protect public health and reduce the burden on global healthcare systems. With new technologies and an increased understanding of the underlining mechanisms of thrombotic diseases, new drugs/therapies will continue to be developed. In addition, these therapies require monitoring to ensure safety and efficacy. This chapter sets the framework for this book.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Haemostasis and the Need for Antithrombotics: An Introduction

  • 章节

  • 发表日期：

    2026年

查看全文
  • John Hogwood,
  • Elaine Gray

摘要

Antithrombotic and antiplatelet agents have been in use for over 100 years, with many listed as WHO essential medicines. Mortality and morbidity caused by cardiovascular diseases and due to arterial and venous thrombosis are increasing globally. The old legacy products such as heparin and warfarin, and the newer generation of agents, such as DOACs and anti-platelet agents, are needed to protect public health and reduce the burden on global healthcare systems. With new technologies and an increased understanding of the underlining mechanisms of thrombotic diseases, new drugs/therapies will continue to be developed. In addition, these therapies require monitoring to ensure safety and efficacy. This chapter sets the framework for this book.